GENFIT-ADR (GNFT) Stock News

USA - Nasdaq - NASDAQ:GNFT - US3722791098 - ADR

4.85 USD

+0.12 (+2.54%)

Last: 11/19/2025, 2:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GNFT Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Benzinga - Mentions: PHAR AGIO PMN KZIA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Benzinga - Mentions: PBM SNGX KPTI SSKN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 years ago - By: Seeking Alpha - Mentions: IVA GILD CBAY

Inventiva stock drops after delay in Phase 3 NASH trial

2 years ago - By: Investor's Business Daily - Mentions: CBAY

Why CymaBay Morphed From Dollar Stock To Biotech Rocket

2 years ago - By: Seeking Alpha

FDA grants priority review of Genfit-Ipsen liver disease drug (NASDAQ:GNFT)

2 years ago - By: Seeking Alpha

Genfit stock rallies 20% after hours on data for liver disease drug (GNFT)

2 years ago - By: Investor's Business Daily - Mentions: CBAY ICPT

Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running

2 years ago - By: Seeking Alpha - Mentions: UBS CBAY ICPT

UBS starts Cymabay at buy, expecting positive Phase 3 data for seladelpar (CBAY)

2 years ago - By: InvestorPlace - Mentions: RNLX LGHL GOGN BHG ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2 years ago - By: Seeking Alpha

Genfit stock soars on Phase 3 win for liver disease drug (NASDAQ:GNFT)

2 years ago - By: Investor's Business Daily - Mentions: ICPT CBAY

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug

3 years ago - By: Seeking Alpha

Genfit stock up on licensing deal for liver disease drug (NASDAQ:GNFT)